HSC-话题@MedSci

#HSC#

46篇内容 | 1089人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2175347, encodeId=d19e21e5347c8, content=<a href='/topic/show?id=3ed881343fa' target=_blank style='color:#2F92EE;'>#肝纤维化#</a> <a href='/topic/show?id=d5ed28667c' target=_blank style='color:#2F92EE;'>#ASK1#</a> <a href='/topic/show?id=4d06914052' target=_blank style='color:#2F92EE;'>#HSC#</a> <a href='/topic/show?id=c3df10866222' target=_blank style='color:#2F92EE;'>#Nur77#</a> <a href='/topic/show?id=190f108663b9' target=_blank style='color:#2F92EE;'>#棘苷#</a> <a href='/topic/show?id=a35910866415' target=_blank style='color:#2F92EE;'>#p38 MAPK#</a>, objectTitle=Eur J Pharmacol：棘苷(SPI)通过靶向Nur77/ASK1/p38 MAPK信号通路抑制活化的肝星状细胞，减轻肝纤维化, objectType=article, longId=805489, objectId=8807805489c8, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20231216/1702737099732_5610093.jpg, objectUrl=/article/show_article.do?id=8807805489c8, replyNumber=0, likeNumber=32, createdTime=2023-12-16, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=8807805489c8, moduleTitle=Eur J Pharmacol：棘苷(SPI)通过靶向Nur77/ASK1/p38 MAPK信号通路抑制活化的肝星状细胞，减轻肝纤维化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8807805489c8)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1658623, encodeId=f97216586239f, content=<a href='/topic/show?id=4d06914052' target=_blank style='color:#2F92EE;'>#HSC#</a>, objectTitle=allo-HSCT后供者细胞上的抗原表达缺失或下调了？, objectType=article, longId=727041, objectId=68b2e270414b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=68b2e270414b, replyNumber=0, likeNumber=45, createdTime=2023-04-01, rootId=0, userName=sjq035, userId=f4bd24890262, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=68b2e270414b, moduleTitle=allo-HSCT后供者细胞上的抗原表达缺失或下调了？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=68b2e270414b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1658624, encodeId=fcf316586241f, content=<a href='/topic/show?id=4d06914052' target=_blank style='color:#2F92EE;'>#HSC#</a>, objectTitle=JNNP:既往疾病改良治疗对AHSCT治疗MS患者安全性和疗效的影响, objectType=article, longId=729933, objectId=fa88e29933d2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fa88e29933d2, replyNumber=0, likeNumber=47, createdTime=2022-12-28, rootId=0, userName=sjq035, userId=f4bd24890262, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fa88e29933d2, moduleTitle=JNNP:既往疾病改良治疗对AHSCT治疗MS患者安全性和疗效的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fa88e29933d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1658622, encodeId=729a16586220d, content=<a href='/topic/show?id=4d06914052' target=_blank style='color:#2F92EE;'>#HSC#</a>, objectTitle=腺病毒感染与移植：造血干细胞移植(HSCT)和实体器官移植(SOT)人群感染情况, objectType=article, longId=221732, objectId=df63221e32a5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df63221e32a5, replyNumber=0, likeNumber=47, createdTime=2022-07-22, rootId=0, userName=爆笑小医, userId=395f25, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df63221e32a5, moduleTitle=腺病毒感染与移植：造血干细胞移植(HSCT)和实体器官移植(SOT)人群感染情况, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df63221e32a5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1658621, encodeId=012b165862114, content=<a href='/topic/show?id=4d06914052' target=_blank style='color:#2F92EE;'>#HSC#</a>, objectTitle=J Clin Oncol：5-aza+HSCT可显著提高MDS老年患者的生存率, objectType=article, longId=214570, objectId=899e2145e0f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=899e2145e0f2, replyNumber=0, likeNumber=47, createdTime=2022-03-25, rootId=0, userName=sjq035, userId=f4bd24890262, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=899e2145e0f2, moduleTitle=J Clin Oncol：5-aza+HSCT可显著提高MDS老年患者的生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=899e2145e0f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1658619, encodeId=d76816586198d, content=<a href='/topic/show?id=4d06914052' target=_blank style='color:#2F92EE;'>#HSC#</a>, objectTitle=J Clin Oncol：强化调理方案不能改善高危型AML/MDS老年患者allo-HSCT后的预后, objectType=article, longId=205037, objectId=941420503ec4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=941420503ec4, replyNumber=0, likeNumber=45, createdTime=2021-10-11, rootId=0, userName=docwu2019, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=941420503ec4, moduleTitle=J Clin Oncol：强化调理方案不能改善高危型AML/MDS老年患者allo-HSCT后的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=941420503ec4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1658620, encodeId=0ffe1658620ad, content=<a href='/topic/show?id=4d06914052' target=_blank style='color:#2F92EE;'>#HSC#</a>, objectTitle=Lancet Haematol：MATRix–RICE方案联合自体HSCT治疗继发CNS浸润的弥漫大B细胞淋巴瘤的疗效显著, objectType=article, longId=206905, objectId=e68520690580, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e68520690580, replyNumber=0, likeNumber=45, createdTime=2021-08-11, rootId=0, userName=sjq035, userId=f4bd24890262, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e68520690580, moduleTitle=Lancet Haematol：MATRix–RICE方案联合自体HSCT治疗继发CNS浸润的弥漫大B细胞淋巴瘤的疗效显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e68520690580)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1658618, encodeId=1b8c1658618b9, content=<a href='/topic/show?id=4d06914052' target=_blank style='color:#2F92EE;'>#HSC#</a>, objectTitle=J Clin Oncol：儿童ALL进行allo-HSCT前的最适清髓方案, objectType=article, longId=204947, objectId=fb6b20494eeb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fb6b20494eeb, replyNumber=0, likeNumber=57, createdTime=2021-03-12, rootId=0, userName=sjq035, userId=f4bd24890262, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fb6b20494eeb, moduleTitle=J Clin Oncol：儿童ALL进行allo-HSCT前的最适清髓方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fb6b20494eeb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1658614, encodeId=ed66165861441, content=<a href='/topic/show?id=4d06914052' target=_blank style='color:#2F92EE;'>#HSC#</a>, objectTitle=Blood：单细胞测序揭示驱动HSC体外生成的转录因子和分子通路, objectType=article, longId=197514, objectId=d44919e5149f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d44919e5149f, replyNumber=0, likeNumber=30, createdTime=2020-12-03, rootId=0, userName=sjq035, userId=f4bd24890262, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d44919e5149f, moduleTitle=Blood：单细胞测序揭示驱动HSC体外生成的转录因子和分子通路, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d44919e5149f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1658617, encodeId=aee6165861e9e, content=<a href='/topic/show?id=4d06914052' target=_blank style='color:#2F92EE;'>#HSC#</a>, objectTitle=Blood：高风险费城染色体阴性ALL成年患者要不要进行allo-HSCT？, objectType=article, longId=203575, objectId=a1f82035e5b3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a1f82035e5b3, replyNumber=0, likeNumber=35, createdTime=2021-07-19, rootId=0, userName=sjq035, userId=f4bd24890262, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a1f82035e5b3, moduleTitle=Blood：高风险费城染色体阴性ALL成年患者要不要进行allo-HSCT？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a1f82035e5b3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1658616, encodeId=f83b165861665, content=<a href='/topic/show?id=4d06914052' target=_blank style='color:#2F92EE;'>#HSC#</a>, objectTitle=JCO：rhG-CSF联合小剂量地西他滨可降低HR-AML患者allo-HSCT后的复发率, objectType=article, longId=203319, objectId=209120331967, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=209120331967, replyNumber=0, likeNumber=55, createdTime=2021-06-28, rootId=0, userName=sjq035, userId=f4bd24890262, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=209120331967, moduleTitle=JCO：rhG-CSF联合小剂量地西他滨可降低HR-AML患者allo-HSCT后的复发率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=209120331967)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1658611, encodeId=73141658611d4, content=<a href='/topic/show?id=4d06914052' target=_blank style='color:#2F92EE;'>#HSC#</a>, objectTitle=Blood：MDH1介导苹果酸-天冬氨酸NADH循环维持胎肝HSC的活性, objectType=article, longId=195274, objectId=5af21952e4f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5af21952e4f9, replyNumber=0, likeNumber=57, createdTime=2020-10-10, rootId=0, userName=sjq035, userId=f4bd24890262, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5af21952e4f9, moduleTitle=Blood：MDH1介导苹果酸-天冬氨酸NADH循环维持胎肝HSC的活性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5af21952e4f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1658612, encodeId=72101658612d0, content=<a href='/topic/show?id=4d06914052' target=_blank style='color:#2F92EE;'>#HSC#</a>, objectTitle=Blood：赖氨酸特异性去甲基化酶1A (LSD1)限制人HSC的体外扩增，是UM171的靶点, objectType=article, longId=196886, objectId=37071968865c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=37071968865c, replyNumber=0, likeNumber=43, createdTime=2020-10-25, rootId=0, userName=sjq035, userId=f4bd24890262, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=37071968865c, moduleTitle=Blood：赖氨酸特异性去甲基化酶1A (LSD1)限制人HSC的体外扩增，是UM171的靶点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=37071968865c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1658615, encodeId=b02e165861516, content=<a href='/topic/show?id=4d06914052' target=_blank style='color:#2F92EE;'>#HSC#</a>, objectTitle=Blood：c-Myc单倍体剂量不足在HSC维持中的作用, objectType=article, longId=200145, objectId=3a0e2001452f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3a0e2001452f, replyNumber=0, likeNumber=33, createdTime=2021-08-06, rootId=0, userName=sjq035, userId=f4bd24890262, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3a0e2001452f, moduleTitle=Blood：c-Myc单倍体剂量不足在HSC维持中的作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3a0e2001452f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1658608, encodeId=40e91658608f3, content=<a href='/topic/show?id=4d06914052' target=_blank style='color:#2F92EE;'>#HSC#</a>, objectTitle=Blood：eculizumab阻断补体激活明显改善高TA-TMA风险患者HSCT后的存活率, objectType=article, longId=186299, objectId=325e1862994a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=325e1862994a, replyNumber=0, likeNumber=50, createdTime=2020-02-15, rootId=0, userName=sjq035, userId=f4bd24890262, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=325e1862994a, moduleTitle=Blood：eculizumab阻断补体激活明显改善高TA-TMA风险患者HSCT后的存活率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=325e1862994a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1658609, encodeId=1573165860910, content=<a href='/topic/show?id=4d06914052' target=_blank style='color:#2F92EE;'>#HSC#</a>, objectTitle=Blood：allo-HSCT后的长期存活者及其供体的克隆造血分析, objectType=article, longId=190570, objectId=10061905e0ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=10061905e0ea, replyNumber=0, likeNumber=0, createdTime=2020-12-23, rootId=0, userName=sjq035, userId=f4bd24890262, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=10061905e0ea, moduleTitle=Blood：allo-HSCT后的长期存活者及其供体的克隆造血分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=10061905e0ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1658607, encodeId=ab3b165860ec7, content=<a href='/topic/show?id=4d06914052' target=_blank style='color:#2F92EE;'>#HSC#</a>, objectTitle=Blood：消化道抗原提呈细胞在alloHSCT后GVHD中的重要作用, objectType=article, longId=182474, objectId=0df41824e457, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0df41824e457, replyNumber=0, likeNumber=39, createdTime=2020-08-01, rootId=0, userName=sjq035, userId=f4bd24890262, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0df41824e457, moduleTitle=Blood：消化道抗原提呈细胞在alloHSCT后GVHD中的重要作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0df41824e457)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1658610, encodeId=c6211658610c6, content=<a href='/topic/show?id=4d06914052' target=_blank style='color:#2F92EE;'>#HSC#</a>, objectTitle=Blood：采用HSCT治疗的恶性血液病患儿的长期预后, objectType=article, longId=191552, objectId=8f6319155265, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f6319155265, replyNumber=0, likeNumber=54, createdTime=2020-06-09, rootId=0, userName=sjq035, userId=f4bd24890262, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f6319155265, moduleTitle=Blood：采用HSCT治疗的恶性血液病患儿的长期预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8f6319155265)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1658613, encodeId=4e181658613ec, content=<a href='/topic/show?id=4d06914052' target=_blank style='color:#2F92EE;'>#HSC#</a>, objectTitle=Blood：BET抑制剂CPI203可促进脐血HSC和巨噬细胞扩增, objectType=article, longId=197061, objectId=1b8719e061c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1b8719e061c8, replyNumber=0, likeNumber=51, createdTime=2021-06-08, rootId=0, userName=sjq035, userId=f4bd24890262, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1b8719e061c8, moduleTitle=Blood：BET抑制剂CPI203可促进脐血HSC和巨噬细胞扩增, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1b8719e061c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1658606, encodeId=da2c1658606e3, content=<a href='/topic/show?id=4d06914052' target=_blank style='color:#2F92EE;'>#HSC#</a>, objectTitle=Blood：骨髓生态位中非造血细胞成分与HSCs的相互作用, objectType=article, longId=176659, objectId=b2c51e665955, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b2c51e665955, replyNumber=0, likeNumber=39, createdTime=2020-05-21, rootId=0, userName=sjq035, userId=f4bd24890262, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b2c51e665955, moduleTitle=Blood：骨髓生态位中非造血细胞成分与HSCs的相互作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b2c51e665955)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

HSC

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#肝纤维化# #ASK1# #HSC# #Nur77# #棘苷# #p38 MAPK#

Eur J Pharmacol：棘苷(SPI)通过靶向Nur77/ASK1/p38 MAPK信号通路抑制活化的肝星状细胞，减轻肝纤维化

2023-12-16发表于上海

sjq035 (审核中...)

前往app查看评论内容

#HSC#

allo-HSCT后供者细胞上的抗原表达缺失或下调了？

2023-04-01

sjq035 (审核中...)

前往app查看评论内容

#HSC#

JNNP:既往疾病改良治疗对AHSCT治疗MS患者安全性和疗效的影响

2022-12-28

爆笑小医 (审核中...)

前往app查看评论内容

#HSC#

腺病毒感染与移植：造血干细胞移植(HSCT)和实体器官移植(SOT)人群感染情况

2022-07-22

sjq035 (审核中...)

前往app查看评论内容

#HSC#

J Clin Oncol：5-aza+HSCT可显著提高MDS老年患者的生存率

2022-03-25

docwu2019 (审核中...)

前往app查看评论内容

#HSC#

J Clin Oncol：强化调理方案不能改善高危型AML/MDS老年患者allo-HSCT后的预后

2021-10-11

sjq035 (审核中...)

前往app查看评论内容

#HSC#

Lancet Haematol：MATRix–RICE方案联合自体HSCT治疗继发CNS浸润的弥漫大B细胞淋巴瘤的疗效显著

2021-08-11

sjq035 (审核中...)

前往app查看评论内容

#HSC#

J Clin Oncol：儿童ALL进行allo-HSCT前的最适清髓方案

2021-03-12

sjq035 (审核中...)

前往app查看评论内容

#HSC#

Blood：单细胞测序揭示驱动HSC体外生成的转录因子和分子通路

2020-12-03

sjq035 (审核中...)

前往app查看评论内容

#HSC#

Blood：高风险费城染色体阴性ALL成年患者要不要进行allo-HSCT？

2021-07-19

sjq035 (审核中...)

前往app查看评论内容

#HSC#

JCO：rhG-CSF联合小剂量地西他滨可降低HR-AML患者allo-HSCT后的复发率

2021-06-28

sjq035 (审核中...)

前往app查看评论内容

#HSC#

Blood：MDH1介导苹果酸-天冬氨酸NADH循环维持胎肝HSC的活性

2020-10-10

sjq035 (审核中...)

前往app查看评论内容

#HSC#

Blood：赖氨酸特异性去甲基化酶1A (LSD1)限制人HSC的体外扩增，是UM171的靶点

2020-10-25

sjq035 (审核中...)

前往app查看评论内容

#HSC#

Blood：c-Myc单倍体剂量不足在HSC维持中的作用

2021-08-06

sjq035 (审核中...)

前往app查看评论内容

#HSC#

Blood：eculizumab阻断补体激活明显改善高TA-TMA风险患者HSCT后的存活率

2020-02-15

sjq035 (审核中...)

前往app查看评论内容

#HSC#

Blood：allo-HSCT后的长期存活者及其供体的克隆造血分析

2020-12-23

sjq035 (审核中...)

前往app查看评论内容

#HSC#

Blood：消化道抗原提呈细胞在alloHSCT后GVHD中的重要作用

2020-08-01

sjq035 (审核中...)

前往app查看评论内容

#HSC#

Blood：采用HSCT治疗的恶性血液病患儿的长期预后

2020-06-09

sjq035 (审核中...)

前往app查看评论内容

#HSC#

Blood：BET抑制剂CPI203可促进脐血HSC和巨噬细胞扩增

2021-06-08

sjq035 (审核中...)

前往app查看评论内容

#HSC#

Blood：骨髓生态位中非造血细胞成分与HSCs的相互作用

2020-05-21

科室
- - 订阅+
  - 更多科室
工具
服务